nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—EGFR—head and neck cancer	0.273	0.636	CbGaD
Erlotinib—CYP1A1—head and neck cancer	0.156	0.364	CbGaD
Erlotinib—EGFR—Docetaxel—head and neck cancer	0.103	0.281	CbGbCtD
Erlotinib—NR1I2—Docetaxel—head and neck cancer	0.0937	0.256	CbGbCtD
Erlotinib—CYP1B1—Docetaxel—head and neck cancer	0.0357	0.0977	CbGbCtD
Erlotinib—ABCG2—Fluorouracil—head and neck cancer	0.0223	0.0608	CbGbCtD
Erlotinib—CYP2D6—Hydroxyurea—head and neck cancer	0.0198	0.0541	CbGbCtD
Erlotinib—ABCG2—Docetaxel—head and neck cancer	0.017	0.0464	CbGbCtD
Erlotinib—ALB—Fluorouracil—head and neck cancer	0.0153	0.0419	CbGbCtD
Erlotinib—CYP2C8—Fluorouracil—head and neck cancer	0.0119	0.0324	CbGbCtD
Erlotinib—CYP3A5—Docetaxel—head and neck cancer	0.00942	0.0257	CbGbCtD
Erlotinib—CYP1A2—Fluorouracil—head and neck cancer	0.00918	0.0251	CbGbCtD
Erlotinib—ABCB1—Vinblastine—head and neck cancer	0.00743	0.0203	CbGbCtD
Erlotinib—CYP2D6—Vinblastine—head and neck cancer	0.007	0.0191	CbGbCtD
Erlotinib—ABCB1—Docetaxel—head and neck cancer	0.00613	0.0167	CbGbCtD
Erlotinib—CYP3A4—Vinblastine—head and neck cancer	0.00445	0.0122	CbGbCtD
Erlotinib—CYP3A4—Docetaxel—head and neck cancer	0.00367	0.01	CbGbCtD
Erlotinib—Nail changes—Fluorouracil—head and neck cancer	0.00361	0.0462	CcSEcCtD
Erlotinib—LTK—tongue—head and neck cancer	0.0027	0.0659	CbGeAlD
Erlotinib—Nail changes—Docetaxel—head and neck cancer	0.00261	0.0333	CcSEcCtD
Erlotinib—Ischaemia—Vinblastine—head and neck cancer	0.00219	0.028	CcSEcCtD
Erlotinib—LTK—mouth—head and neck cancer	0.00182	0.0443	CbGeAlD
Erlotinib—Pulmonary fibrosis—Hydroxyurea—head and neck cancer	0.00166	0.0212	CcSEcCtD
Erlotinib—Lung infiltration—Hydroxyurea—head and neck cancer	0.00155	0.0199	CcSEcCtD
Erlotinib—ULK3—tongue—head and neck cancer	0.00147	0.0358	CbGeAlD
Erlotinib—ORM1—saliva—head and neck cancer	0.00147	0.0358	CbGeAlD
Erlotinib—Gastrointestinal perforation—Docetaxel—head and neck cancer	0.00145	0.0185	CcSEcCtD
Erlotinib—Acute respiratory distress syndrome—Docetaxel—head and neck cancer	0.00145	0.0185	CcSEcCtD
Erlotinib—Mucosal inflammation—Hydroxyurea—head and neck cancer	0.00131	0.0168	CcSEcCtD
Erlotinib—Skin hyperpigmentation—Hydroxyurea—head and neck cancer	0.00122	0.0157	CcSEcCtD
Erlotinib—Peptic ulcer—Vinblastine—head and neck cancer	0.00119	0.0153	CcSEcCtD
Erlotinib—MKNK1—hair follicle—head and neck cancer	0.00119	0.0289	CbGeAlD
Erlotinib—Vandetanib—VEGFA—head and neck cancer	0.00115	0.322	CrCbGaD
Erlotinib—Ileus—Vinblastine—head and neck cancer	0.00113	0.0144	CcSEcCtD
Erlotinib—Blister—Hydroxyurea—head and neck cancer	0.00101	0.0129	CcSEcCtD
Erlotinib—ULK3—mouth—head and neck cancer	0.000988	0.0241	CbGeAlD
Erlotinib—Vandetanib—EGFR—head and neck cancer	0.000974	0.272	CrCbGaD
Erlotinib—Hepatotoxicity—Hydroxyurea—head and neck cancer	0.000943	0.0121	CcSEcCtD
Erlotinib—Gefitinib—EGFR—head and neck cancer	0.000926	0.258	CrCbGaD
Erlotinib—JAK3—connective tissue—head and neck cancer	0.00089	0.0217	CbGeAlD
Erlotinib—Skin hyperpigmentation—Fluorouracil—head and neck cancer	0.000881	0.0113	CcSEcCtD
Erlotinib—Cellulitis—Vinblastine—head and neck cancer	0.000878	0.0112	CcSEcCtD
Erlotinib—Pulmonary fibrosis—Docetaxel—head and neck cancer	0.00086	0.011	CcSEcCtD
Erlotinib—Tenderness—Hydroxyurea—head and neck cancer	0.000834	0.0107	CcSEcCtD
Erlotinib—Bone pain—Vinblastine—head and neck cancer	0.000833	0.0107	CcSEcCtD
Erlotinib—Nail disorder—Fluorouracil—head and neck cancer	0.000808	0.0103	CcSEcCtD
Erlotinib—Interstitial pneumonia—Docetaxel—head and neck cancer	0.000783	0.01	CcSEcCtD
Erlotinib—Blister—Fluorouracil—head and neck cancer	0.000727	0.0093	CcSEcCtD
Erlotinib—PIP4K2C—parotid gland—head and neck cancer	0.000721	0.0176	CbGeAlD
Erlotinib—FLT3—connective tissue—head and neck cancer	0.000702	0.0171	CbGeAlD
Erlotinib—Skin exfoliation—Hydroxyurea—head and neck cancer	0.000695	0.00889	CcSEcCtD
Erlotinib—PIP4K2C—saliva-secreting gland—head and neck cancer	0.00069	0.0168	CbGeAlD
Erlotinib—ULK3—parotid gland—head and neck cancer	0.000688	0.0168	CbGeAlD
Erlotinib—TNK1—trachea—head and neck cancer	0.000686	0.0167	CbGeAlD
Erlotinib—Mucosal inflammation—Docetaxel—head and neck cancer	0.000683	0.00874	CcSEcCtD
Erlotinib—Foetor hepaticus—Docetaxel—head and neck cancer	0.000666	0.00852	CcSEcCtD
Erlotinib—ULK3—saliva-secreting gland—head and neck cancer	0.000659	0.0161	CbGeAlD
Erlotinib—LTK—head—head and neck cancer	0.000656	0.016	CbGeAlD
Erlotinib—NR1I2—head—head and neck cancer	0.000656	0.016	CbGeAlD
Erlotinib—JAK3—lymphoid tissue—head and neck cancer	0.000651	0.0159	CbGeAlD
Erlotinib—AURKC—thyroid gland—head and neck cancer	0.000638	0.0156	CbGeAlD
Erlotinib—Skin hyperpigmentation—Docetaxel—head and neck cancer	0.000636	0.00813	CcSEcCtD
Erlotinib—Deep vein thrombosis—Docetaxel—head and neck cancer	0.000622	0.00795	CcSEcCtD
Erlotinib—SLK—parotid gland—head and neck cancer	0.000613	0.015	CbGeAlD
Erlotinib—Tenderness—Fluorouracil—head and neck cancer	0.000601	0.00768	CcSEcCtD
Erlotinib—Cerebrovascular accident—Vinblastine—head and neck cancer	0.000591	0.00756	CcSEcCtD
Erlotinib—JAK3—thyroid gland—head and neck cancer	0.000591	0.0144	CbGeAlD
Erlotinib—Hepatic failure—Hydroxyurea—head and neck cancer	0.000588	0.00752	CcSEcCtD
Erlotinib—SLK—saliva-secreting gland—head and neck cancer	0.000588	0.0143	CbGeAlD
Erlotinib—Nail disorder—Docetaxel—head and neck cancer	0.000583	0.00746	CcSEcCtD
Erlotinib—Cellulitis—Fluorouracil—head and neck cancer	0.000576	0.00737	CcSEcCtD
Erlotinib—Renal failure acute—Hydroxyurea—head and neck cancer	0.000572	0.00732	CcSEcCtD
Erlotinib—CYP1B1—hair follicle—head and neck cancer	0.00057	0.0139	CbGeAlD
Erlotinib—AURKC—head—head and neck cancer	0.000566	0.0138	CbGeAlD
Erlotinib—Liver disorder—Docetaxel—head and neck cancer	0.000555	0.0071	CcSEcCtD
Erlotinib—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.000553	0.00707	CcSEcCtD
Erlotinib—TNK1—thyroid gland—head and neck cancer	0.000543	0.0132	CbGeAlD
Erlotinib—Inflammation—Fluorouracil—head and neck cancer	0.00054	0.00691	CcSEcCtD
Erlotinib—Interstitial lung disease—Docetaxel—head and neck cancer	0.000534	0.00683	CcSEcCtD
Erlotinib—Ileus—Docetaxel—head and neck cancer	0.000534	0.00683	CcSEcCtD
Erlotinib—PIP4K2C—trachea—head and neck cancer	0.000533	0.013	CbGeAlD
Erlotinib—Gefitinib—CYP1A1—head and neck cancer	0.00053	0.148	CrCbGaD
Erlotinib—JAK3—head—head and neck cancer	0.000525	0.0128	CbGeAlD
Erlotinib—EPHA6—head—head and neck cancer	0.000525	0.0128	CbGeAlD
Erlotinib—FLT3—lymphoid tissue—head and neck cancer	0.000513	0.0125	CbGeAlD
Erlotinib—ULK3—trachea—head and neck cancer	0.000508	0.0124	CbGeAlD
Erlotinib—Hepatotoxicity—Docetaxel—head and neck cancer	0.00049	0.00626	CcSEcCtD
Erlotinib—MAP3K19—head—head and neck cancer	0.000477	0.0116	CbGeAlD
Erlotinib—MAP2K5—parotid gland—head and neck cancer	0.000476	0.0116	CbGeAlD
Erlotinib—Rigors—Docetaxel—head and neck cancer	0.000463	0.00592	CcSEcCtD
Erlotinib—LTK—lymph node—head and neck cancer	0.000459	0.0112	CbGeAlD
Erlotinib—MAP2K5—saliva-secreting gland—head and neck cancer	0.000456	0.0111	CbGeAlD
Erlotinib—Sepsis—Fluorouracil—head and neck cancer	0.000455	0.00582	CcSEcCtD
Erlotinib—SLK—trachea—head and neck cancer	0.000453	0.011	CbGeAlD
Erlotinib—Pancreatitis—Hydroxyurea—head and neck cancer	0.000448	0.00573	CcSEcCtD
Erlotinib—ABL2—thyroid gland—head and neck cancer	0.000445	0.0109	CbGeAlD
Erlotinib—Depression—Vinblastine—head and neck cancer	0.000445	0.00569	CcSEcCtD
Erlotinib—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00044	0.00563	CcSEcCtD
Erlotinib—Myocardial infarction—Vinblastine—head and neck cancer	0.000438	0.0056	CcSEcCtD
Erlotinib—Neuropathy peripheral—Vinblastine—head and neck cancer	0.000438	0.0056	CcSEcCtD
Erlotinib—EGFR—thyroid gland—head and neck cancer	0.000435	0.0106	CbGeAlD
Erlotinib—Neutropenia—Hydroxyurea—head and neck cancer	0.000427	0.00546	CcSEcCtD
Erlotinib—PIP4K2C—thyroid gland—head and neck cancer	0.000421	0.0103	CbGeAlD
Erlotinib—MKNK1—lymphoid tissue—head and neck cancer	0.000417	0.0102	CbGeAlD
Erlotinib—Drug interaction—Docetaxel—head and neck cancer	0.000408	0.00521	CcSEcCtD
Erlotinib—Infestation NOS—Hydroxyurea—head and neck cancer	0.000407	0.00521	CcSEcCtD
Erlotinib—Infestation—Hydroxyurea—head and neck cancer	0.000407	0.00521	CcSEcCtD
Erlotinib—Haemoglobin—Vinblastine—head and neck cancer	0.000403	0.00515	CcSEcCtD
Erlotinib—ULK3—thyroid gland—head and neck cancer	0.000402	0.00981	CbGeAlD
Erlotinib—Haemorrhage—Vinblastine—head and neck cancer	0.000401	0.00513	CcSEcCtD
Erlotinib—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000399	0.00511	CcSEcCtD
Erlotinib—Dermatitis bullous—Fluorouracil—head and neck cancer	0.000398	0.00509	CcSEcCtD
Erlotinib—Stomatitis—Hydroxyurea—head and neck cancer	0.000397	0.00508	CcSEcCtD
Erlotinib—AURKC—lymph node—head and neck cancer	0.000397	0.00967	CbGeAlD
Erlotinib—Bone pain—Docetaxel—head and neck cancer	0.000395	0.00505	CcSEcCtD
Erlotinib—Inflammation—Docetaxel—head and neck cancer	0.00039	0.00499	CcSEcCtD
Erlotinib—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000385	0.00493	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00038	0.00486	CcSEcCtD
Erlotinib—MKNK1—thyroid gland—head and neck cancer	0.000379	0.00923	CbGeAlD
Erlotinib—Hepatocellular injury—Docetaxel—head and neck cancer	0.000378	0.00484	CcSEcCtD
Erlotinib—PIP4K2C—head—head and neck cancer	0.000374	0.00911	CbGeAlD
Erlotinib—ABL1—parotid gland—head and neck cancer	0.000367	0.00896	CbGeAlD
Erlotinib—Haemoglobin—Hydroxyurea—head and neck cancer	0.000367	0.0047	CcSEcCtD
Erlotinib—JAK3—lymph node—head and neck cancer	0.000367	0.00895	CbGeAlD
Erlotinib—Haemorrhage—Hydroxyurea—head and neck cancer	0.000366	0.00468	CcSEcCtD
Erlotinib—Colitis—Docetaxel—head and neck cancer	0.000363	0.00464	CcSEcCtD
Erlotinib—Skin exfoliation—Docetaxel—head and neck cancer	0.000361	0.00462	CcSEcCtD
Erlotinib—SLK—thyroid gland—head and neck cancer	0.000359	0.00874	CbGeAlD
Erlotinib—ULK3—head—head and neck cancer	0.000357	0.0087	CbGeAlD
Erlotinib—Neuropathy—Docetaxel—head and neck cancer	0.000355	0.00454	CcSEcCtD
Erlotinib—Alopecia—Vinblastine—head and neck cancer	0.000354	0.00453	CcSEcCtD
Erlotinib—ABL1—saliva-secreting gland—head and neck cancer	0.000352	0.00858	CbGeAlD
Erlotinib—MAP2K5—trachea—head and neck cancer	0.000352	0.00858	CbGeAlD
Erlotinib—Dry skin—Fluorouracil—head and neck cancer	0.000349	0.00446	CcSEcCtD
Erlotinib—STK10—lymphoid tissue—head and neck cancer	0.000343	0.00837	CbGeAlD
Erlotinib—TNK1—lymph node—head and neck cancer	0.000337	0.00822	CbGeAlD
Erlotinib—MKNK1—head—head and neck cancer	0.000336	0.00819	CbGeAlD
Erlotinib—Dysphagia—Fluorouracil—head and neck cancer	0.000329	0.0042	CcSEcCtD
Erlotinib—Sepsis—Docetaxel—head and neck cancer	0.000328	0.0042	CcSEcCtD
Erlotinib—Chills—Hydroxyurea—head and neck cancer	0.000328	0.0042	CcSEcCtD
Erlotinib—ABL1—connective tissue—head and neck cancer	0.000323	0.00789	CbGeAlD
Erlotinib—Alopecia—Hydroxyurea—head and neck cancer	0.000323	0.00413	CcSEcCtD
Erlotinib—Erythema—Hydroxyurea—head and neck cancer	0.000318	0.00407	CcSEcCtD
Erlotinib—CYP1A1—mouth—head and neck cancer	0.000316	0.0077	CbGeAlD
Erlotinib—STK10—thyroid gland—head and neck cancer	0.000312	0.0076	CbGeAlD
Erlotinib—Hepatic failure—Docetaxel—head and neck cancer	0.000305	0.00391	CcSEcCtD
Erlotinib—Pneumonia—Fluorouracil—head and neck cancer	0.000295	0.00377	CcSEcCtD
Erlotinib—Infestation—Fluorouracil—head and neck cancer	0.000293	0.00375	CcSEcCtD
Erlotinib—Infestation NOS—Fluorouracil—head and neck cancer	0.000293	0.00375	CcSEcCtD
Erlotinib—FLT3—lymph node—head and neck cancer	0.00029	0.00706	CbGeAlD
Erlotinib—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000289	0.0037	CcSEcCtD
Erlotinib—Renal impairment—Docetaxel—head and neck cancer	0.000288	0.00369	CcSEcCtD
Erlotinib—Myocardial infarction—Fluorouracil—head and neck cancer	0.000287	0.00367	CcSEcCtD
Erlotinib—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000287	0.00367	CcSEcCtD
Erlotinib—Dermatitis bullous—Docetaxel—head and neck cancer	0.000287	0.00367	CcSEcCtD
Erlotinib—Stomatitis—Fluorouracil—head and neck cancer	0.000286	0.00365	CcSEcCtD
Erlotinib—Conjunctivitis—Fluorouracil—head and neck cancer	0.000285	0.00364	CcSEcCtD
Erlotinib—Thrombocytopenia—Vinblastine—head and neck cancer	0.000279	0.00357	CcSEcCtD
Erlotinib—MAP2K5—thyroid gland—head and neck cancer	0.000278	0.00679	CbGeAlD
Erlotinib—ABL2—lymph node—head and neck cancer	0.000277	0.00674	CbGeAlD
Erlotinib—STK10—head—head and neck cancer	0.000277	0.00674	CbGeAlD
Erlotinib—Epistaxis—Fluorouracil—head and neck cancer	0.000276	0.00354	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000275	0.00351	CcSEcCtD
Erlotinib—CYP1B1—connective tissue—head and neck cancer	0.000274	0.00668	CbGeAlD
Erlotinib—ABL1—trachea—head and neck cancer	0.000272	0.00662	CbGeAlD
Erlotinib—Anorexia—Vinblastine—head and neck cancer	0.000271	0.00347	CcSEcCtD
Erlotinib—EGFR—lymph node—head and neck cancer	0.00027	0.00658	CbGeAlD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000269	0.00344	CcSEcCtD
Erlotinib—Haemoglobin—Fluorouracil—head and neck cancer	0.000264	0.00338	CcSEcCtD
Erlotinib—Haemorrhage—Fluorouracil—head and neck cancer	0.000263	0.00337	CcSEcCtD
Erlotinib—PIP4K2C—lymph node—head and neck cancer	0.000262	0.00638	CbGeAlD
Erlotinib—Oedema—Hydroxyurea—head and neck cancer	0.00026	0.00332	CcSEcCtD
Erlotinib—Infection—Hydroxyurea—head and neck cancer	0.000258	0.0033	CcSEcCtD
Erlotinib—Dehydration—Docetaxel—head and neck cancer	0.000255	0.00327	CcSEcCtD
Erlotinib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000255	0.00326	CcSEcCtD
Erlotinib—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000254	0.00325	CcSEcCtD
Erlotinib—Skin disorder—Hydroxyurea—head and neck cancer	0.000252	0.00323	CcSEcCtD
Erlotinib—Dry skin—Docetaxel—head and neck cancer	0.000252	0.00322	CcSEcCtD
Erlotinib—ULK3—lymph node—head and neck cancer	0.00025	0.00609	CbGeAlD
Erlotinib—Anorexia—Hydroxyurea—head and neck cancer	0.000248	0.00317	CcSEcCtD
Erlotinib—Decreased appetite—Vinblastine—head and neck cancer	0.000248	0.00317	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000247	0.00316	CcSEcCtD
Erlotinib—MAP2K5—head—head and neck cancer	0.000247	0.00602	CbGeAlD
Erlotinib—Pain—Vinblastine—head and neck cancer	0.000244	0.00311	CcSEcCtD
Erlotinib—Constipation—Vinblastine—head and neck cancer	0.000244	0.00311	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000242	0.0031	CcSEcCtD
Erlotinib—Dysphagia—Docetaxel—head and neck cancer	0.000237	0.00303	CcSEcCtD
Erlotinib—ABL1—lymphoid tissue—head and neck cancer	0.000236	0.00577	CbGeAlD
Erlotinib—MKNK1—lymph node—head and neck cancer	0.000235	0.00573	CbGeAlD
Erlotinib—Arrhythmia—Fluorouracil—head and neck cancer	0.000235	0.00301	CcSEcCtD
Erlotinib—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000233	0.00298	CcSEcCtD
Erlotinib—Alopecia—Fluorouracil—head and neck cancer	0.000233	0.00297	CcSEcCtD
Erlotinib—ABCG2—parotid gland—head and neck cancer	0.000232	0.00565	CbGeAlD
Erlotinib—Dyspnoea—Hydroxyurea—head and neck cancer	0.000232	0.00296	CcSEcCtD
Erlotinib—Erythema—Fluorouracil—head and neck cancer	0.000229	0.00293	CcSEcCtD
Erlotinib—Dyspepsia—Hydroxyurea—head and neck cancer	0.000229	0.00292	CcSEcCtD
Erlotinib—Decreased appetite—Hydroxyurea—head and neck cancer	0.000226	0.00289	CcSEcCtD
Erlotinib—Abdominal pain—Vinblastine—head and neck cancer	0.000225	0.00288	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000224	0.00287	CcSEcCtD
Erlotinib—Fatigue—Hydroxyurea—head and neck cancer	0.000224	0.00286	CcSEcCtD
Erlotinib—SLK—lymph node—head and neck cancer	0.000223	0.00543	CbGeAlD
Erlotinib—Pain—Hydroxyurea—head and neck cancer	0.000222	0.00284	CcSEcCtD
Erlotinib—Constipation—Hydroxyurea—head and neck cancer	0.000222	0.00284	CcSEcCtD
Erlotinib—ABCG2—saliva-secreting gland—head and neck cancer	0.000222	0.00541	CbGeAlD
Erlotinib—Neutropenia—Docetaxel—head and neck cancer	0.000222	0.00284	CcSEcCtD
Erlotinib—CYP1A1—parotid gland—head and neck cancer	0.00022	0.00536	CbGeAlD
Erlotinib—SLCO2B1—thyroid gland—head and neck cancer	0.000217	0.00528	CbGeAlD
Erlotinib—ABL1—thyroid gland—head and neck cancer	0.000215	0.00524	CbGeAlD
Erlotinib—Weight decreased—Docetaxel—head and neck cancer	0.000215	0.00275	CcSEcCtD
Erlotinib—Pneumonia—Docetaxel—head and neck cancer	0.000213	0.00272	CcSEcCtD
Erlotinib—Infestation—Docetaxel—head and neck cancer	0.000212	0.00271	CcSEcCtD
Erlotinib—Infestation NOS—Docetaxel—head and neck cancer	0.000212	0.00271	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.00021	0.00268	CcSEcCtD
Erlotinib—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000209	0.00267	CcSEcCtD
Erlotinib—Renal failure—Docetaxel—head and neck cancer	0.000208	0.00266	CcSEcCtD
Erlotinib—Myocardial infarction—Docetaxel—head and neck cancer	0.000207	0.00265	CcSEcCtD
Erlotinib—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000207	0.00265	CcSEcCtD
Erlotinib—Stomatitis—Docetaxel—head and neck cancer	0.000206	0.00264	CcSEcCtD
Erlotinib—Conjunctivitis—Docetaxel—head and neck cancer	0.000206	0.00263	CcSEcCtD
Erlotinib—Body temperature increased—Hydroxyurea—head and neck cancer	0.000205	0.00263	CcSEcCtD
Erlotinib—Asthenia—Vinblastine—head and neck cancer	0.000204	0.00261	CcSEcCtD
Erlotinib—CYP1B1—lymphoid tissue—head and neck cancer	0.0002	0.00488	CbGeAlD
Erlotinib—Hepatobiliary disease—Docetaxel—head and neck cancer	0.0002	0.00256	CcSEcCtD
Erlotinib—Epistaxis—Docetaxel—head and neck cancer	0.0002	0.00255	CcSEcCtD
Erlotinib—Chest pain—Fluorouracil—head and neck cancer	0.000195	0.00249	CcSEcCtD
Erlotinib—Myalgia—Fluorouracil—head and neck cancer	0.000195	0.00249	CcSEcCtD
Erlotinib—Diarrhoea—Vinblastine—head and neck cancer	0.000195	0.00249	CcSEcCtD
Erlotinib—STK10—lymph node—head and neck cancer	0.000194	0.00472	CbGeAlD
Erlotinib—SLCO2B1—head—head and neck cancer	0.000192	0.00469	CbGeAlD
Erlotinib—Haemoglobin—Docetaxel—head and neck cancer	0.000191	0.00244	CcSEcCtD
Erlotinib—ABL1—head—head and neck cancer	0.000191	0.00465	CbGeAlD
Erlotinib—Haemorrhage—Docetaxel—head and neck cancer	0.00019	0.00243	CcSEcCtD
Erlotinib—Hepatitis—Docetaxel—head and neck cancer	0.00019	0.00243	CcSEcCtD
Erlotinib—Dizziness—Vinblastine—head and neck cancer	0.000188	0.00241	CcSEcCtD
Erlotinib—Urinary tract disorder—Docetaxel—head and neck cancer	0.000188	0.0024	CcSEcCtD
Erlotinib—Oedema—Fluorouracil—head and neck cancer	0.000187	0.00239	CcSEcCtD
Erlotinib—Connective tissue disorder—Docetaxel—head and neck cancer	0.000187	0.00239	CcSEcCtD
Erlotinib—Asthenia—Hydroxyurea—head and neck cancer	0.000186	0.00238	CcSEcCtD
Erlotinib—Urethral disorder—Docetaxel—head and neck cancer	0.000186	0.00238	CcSEcCtD
Erlotinib—Infection—Fluorouracil—head and neck cancer	0.000186	0.00238	CcSEcCtD
Erlotinib—CYP1A1—epithelium—head and neck cancer	0.000184	0.00448	CbGeAlD
Erlotinib—Nervous system disorder—Fluorouracil—head and neck cancer	0.000183	0.00234	CcSEcCtD
Erlotinib—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000183	0.00234	CcSEcCtD
Erlotinib—CYP1B1—thyroid gland—head and neck cancer	0.000182	0.00443	CbGeAlD
Erlotinib—Vomiting—Vinblastine—head and neck cancer	0.000181	0.00232	CcSEcCtD
Erlotinib—Erythema multiforme—Docetaxel—head and neck cancer	0.00018	0.0023	CcSEcCtD
Erlotinib—Headache—Vinblastine—head and neck cancer	0.000178	0.00228	CcSEcCtD
Erlotinib—Anorexia—Fluorouracil—head and neck cancer	0.000178	0.00228	CcSEcCtD
Erlotinib—Diarrhoea—Hydroxyurea—head and neck cancer	0.000178	0.00227	CcSEcCtD
Erlotinib—Eye disorder—Docetaxel—head and neck cancer	0.000177	0.00227	CcSEcCtD
Erlotinib—MAP2K5—lymph node—head and neck cancer	0.000173	0.00422	CbGeAlD
Erlotinib—Dizziness—Hydroxyurea—head and neck cancer	0.000172	0.0022	CcSEcCtD
Erlotinib—Mediastinal disorder—Docetaxel—head and neck cancer	0.000171	0.00219	CcSEcCtD
Erlotinib—Chills—Docetaxel—head and neck cancer	0.00017	0.00218	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00017	0.00218	CcSEcCtD
Erlotinib—Arrhythmia—Docetaxel—head and neck cancer	0.00017	0.00217	CcSEcCtD
Erlotinib—Nausea—Vinblastine—head and neck cancer	0.000169	0.00216	CcSEcCtD
Erlotinib—Insomnia—Fluorouracil—head and neck cancer	0.000169	0.00216	CcSEcCtD
Erlotinib—Alopecia—Docetaxel—head and neck cancer	0.000168	0.00215	CcSEcCtD
Erlotinib—Dyspnoea—Fluorouracil—head and neck cancer	0.000167	0.00213	CcSEcCtD
Erlotinib—Mental disorder—Docetaxel—head and neck cancer	0.000166	0.00213	CcSEcCtD
Erlotinib—Erythema—Docetaxel—head and neck cancer	0.000165	0.00211	CcSEcCtD
Erlotinib—Malnutrition—Docetaxel—head and neck cancer	0.000165	0.00211	CcSEcCtD
Erlotinib—Vomiting—Hydroxyurea—head and neck cancer	0.000165	0.00211	CcSEcCtD
Erlotinib—Dyspepsia—Fluorouracil—head and neck cancer	0.000165	0.0021	CcSEcCtD
Erlotinib—Rash—Hydroxyurea—head and neck cancer	0.000164	0.00209	CcSEcCtD
Erlotinib—Dermatitis—Hydroxyurea—head and neck cancer	0.000164	0.00209	CcSEcCtD
Erlotinib—Headache—Hydroxyurea—head and neck cancer	0.000163	0.00208	CcSEcCtD
Erlotinib—CYP1A1—trachea—head and neck cancer	0.000163	0.00396	CbGeAlD
Erlotinib—Decreased appetite—Fluorouracil—head and neck cancer	0.000163	0.00208	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000161	0.00206	CcSEcCtD
Erlotinib—CYP1B1—head—head and neck cancer	0.000161	0.00393	CbGeAlD
Erlotinib—Back pain—Docetaxel—head and neck cancer	0.00016	0.00205	CcSEcCtD
Erlotinib—Pain—Fluorouracil—head and neck cancer	0.00016	0.00204	CcSEcCtD
Erlotinib—Nausea—Hydroxyurea—head and neck cancer	0.000154	0.00197	CcSEcCtD
Erlotinib—Syncope—Docetaxel—head and neck cancer	0.000148	0.0019	CcSEcCtD
Erlotinib—Body temperature increased—Fluorouracil—head and neck cancer	0.000148	0.00189	CcSEcCtD
Erlotinib—Loss of consciousness—Docetaxel—head and neck cancer	0.000145	0.00186	CcSEcCtD
Erlotinib—Cough—Docetaxel—head and neck cancer	0.000144	0.00185	CcSEcCtD
Erlotinib—Arthralgia—Docetaxel—head and neck cancer	0.000141	0.0018	CcSEcCtD
Erlotinib—Chest pain—Docetaxel—head and neck cancer	0.000141	0.0018	CcSEcCtD
Erlotinib—Myalgia—Docetaxel—head and neck cancer	0.000141	0.0018	CcSEcCtD
Erlotinib—ORM1—lymph node—head and neck cancer	0.00014	0.00342	CbGeAlD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00014	0.00179	CcSEcCtD
Erlotinib—ABCG2—thyroid gland—head and neck cancer	0.000135	0.0033	CbGeAlD
Erlotinib—Oedema—Docetaxel—head and neck cancer	0.000135	0.00173	CcSEcCtD
Erlotinib—SLCO2B1—lymph node—head and neck cancer	0.000135	0.00328	CbGeAlD
Erlotinib—Infection—Docetaxel—head and neck cancer	0.000134	0.00171	CcSEcCtD
Erlotinib—ABL1—lymph node—head and neck cancer	0.000133	0.00325	CbGeAlD
Erlotinib—Shock—Docetaxel—head and neck cancer	0.000133	0.0017	CcSEcCtD
Erlotinib—Nervous system disorder—Docetaxel—head and neck cancer	0.000132	0.00169	CcSEcCtD
Erlotinib—Pruritus—Fluorouracil—head and neck cancer	0.000132	0.00169	CcSEcCtD
Erlotinib—Thrombocytopenia—Docetaxel—head and neck cancer	0.000132	0.00169	CcSEcCtD
Erlotinib—Skin disorder—Docetaxel—head and neck cancer	0.000131	0.00168	CcSEcCtD
Erlotinib—CYP1A2—thyroid gland—head and neck cancer	0.00013	0.00318	CbGeAlD
Erlotinib—Anorexia—Docetaxel—head and neck cancer	0.000129	0.00164	CcSEcCtD
Erlotinib—CYP1A1—thyroid gland—head and neck cancer	0.000129	0.00314	CbGeAlD
Erlotinib—Diarrhoea—Fluorouracil—head and neck cancer	0.000128	0.00164	CcSEcCtD
Erlotinib—Dizziness—Fluorouracil—head and neck cancer	0.000124	0.00158	CcSEcCtD
Erlotinib—ALB—lymph node—head and neck cancer	0.000123	0.003	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000123	0.00157	CcSEcCtD
Erlotinib—Insomnia—Docetaxel—head and neck cancer	0.000122	0.00156	CcSEcCtD
Erlotinib—Dyspnoea—Docetaxel—head and neck cancer	0.00012	0.00154	CcSEcCtD
Erlotinib—Vomiting—Fluorouracil—head and neck cancer	0.000119	0.00152	CcSEcCtD
Erlotinib—Dyspepsia—Docetaxel—head and neck cancer	0.000119	0.00152	CcSEcCtD
Erlotinib—Rash—Fluorouracil—head and neck cancer	0.000118	0.00151	CcSEcCtD
Erlotinib—Dermatitis—Fluorouracil—head and neck cancer	0.000118	0.00151	CcSEcCtD
Erlotinib—Decreased appetite—Docetaxel—head and neck cancer	0.000117	0.0015	CcSEcCtD
Erlotinib—Headache—Fluorouracil—head and neck cancer	0.000117	0.0015	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000116	0.00149	CcSEcCtD
Erlotinib—Fatigue—Docetaxel—head and neck cancer	0.000116	0.00149	CcSEcCtD
Erlotinib—Constipation—Docetaxel—head and neck cancer	0.000115	0.00148	CcSEcCtD
Erlotinib—Pain—Docetaxel—head and neck cancer	0.000115	0.00148	CcSEcCtD
Erlotinib—CYP1A1—head—head and neck cancer	0.000114	0.00278	CbGeAlD
Erlotinib—CYP1B1—lymph node—head and neck cancer	0.000113	0.00275	CbGeAlD
Erlotinib—Nausea—Fluorouracil—head and neck cancer	0.000111	0.00142	CcSEcCtD
Erlotinib—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00011	0.00141	CcSEcCtD
Erlotinib—Body temperature increased—Docetaxel—head and neck cancer	0.000107	0.00136	CcSEcCtD
Erlotinib—Abdominal pain—Docetaxel—head and neck cancer	0.000107	0.00136	CcSEcCtD
Erlotinib—Asthenia—Docetaxel—head and neck cancer	9.68e-05	0.00124	CcSEcCtD
Erlotinib—ABCB1—epithelium—head and neck cancer	9.55e-05	0.00233	CbGeAlD
Erlotinib—Pruritus—Docetaxel—head and neck cancer	9.55e-05	0.00122	CcSEcCtD
Erlotinib—Diarrhoea—Docetaxel—head and neck cancer	9.23e-05	0.00118	CcSEcCtD
Erlotinib—Dizziness—Docetaxel—head and neck cancer	8.92e-05	0.00114	CcSEcCtD
Erlotinib—Vomiting—Docetaxel—head and neck cancer	8.58e-05	0.0011	CcSEcCtD
Erlotinib—Rash—Docetaxel—head and neck cancer	8.51e-05	0.00109	CcSEcCtD
Erlotinib—Dermatitis—Docetaxel—head and neck cancer	8.5e-05	0.00109	CcSEcCtD
Erlotinib—Headache—Docetaxel—head and neck cancer	8.45e-05	0.00108	CcSEcCtD
Erlotinib—ABCB1—trachea—head and neck cancer	8.44e-05	0.00206	CbGeAlD
Erlotinib—ABCG2—lymph node—head and neck cancer	8.41e-05	0.00205	CbGeAlD
Erlotinib—CYP2D6—head—head and neck cancer	8.24e-05	0.00201	CbGeAlD
Erlotinib—Nausea—Docetaxel—head and neck cancer	8.01e-05	0.00103	CcSEcCtD
Erlotinib—CYP1A1—lymph node—head and neck cancer	7.99e-05	0.00195	CbGeAlD
Erlotinib—ABCB1—lymphoid tissue—head and neck cancer	7.35e-05	0.00179	CbGeAlD
Erlotinib—ABCB1—thyroid gland—head and neck cancer	6.68e-05	0.00163	CbGeAlD
Erlotinib—ABCB1—head—head and neck cancer	5.93e-05	0.00144	CbGeAlD
Erlotinib—ABCB1—lymph node—head and neck cancer	4.15e-05	0.00101	CbGeAlD
Erlotinib—ALB—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	9.44e-06	0.000115	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GSTM1—head and neck cancer	9.42e-06	0.000115	CbGpPWpGaD
Erlotinib—EGFR—Immune System—BCL2L1—head and neck cancer	9.37e-06	0.000114	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—PTEN—head and neck cancer	9.35e-06	0.000114	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—MAPK3—head and neck cancer	9.35e-06	0.000114	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	9.29e-06	0.000113	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	9.29e-06	0.000113	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MAPK3—head and neck cancer	9.12e-06	0.000111	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—YAP1—head and neck cancer	9.12e-06	0.000111	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MAPK3—head and neck cancer	9.05e-06	0.00011	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GPX1—head and neck cancer	9.03e-06	0.00011	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PTEN—head and neck cancer	8.98e-06	0.000109	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CASP8—head and neck cancer	8.97e-06	0.000109	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CYP1A1—head and neck cancer	8.93e-06	0.000109	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—MAPK1—head and neck cancer	8.9e-06	0.000108	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EGFR—head and neck cancer	8.9e-06	0.000108	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—HRAS—head and neck cancer	8.89e-06	0.000108	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—TYMS—head and neck cancer	8.89e-06	0.000108	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CDH1—head and neck cancer	8.86e-06	0.000108	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—DPYD—head and neck cancer	8.81e-06	0.000107	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GSTM1—head and neck cancer	8.79e-06	0.000107	CbGpPWpGaD
Erlotinib—MKNK1—Disease—AKT1—head and neck cancer	8.79e-06	0.000107	CbGpPWpGaD
Erlotinib—JAK3—Immune System—PIK3CA—head and neck cancer	8.78e-06	0.000107	CbGpPWpGaD
Erlotinib—ALB—Metabolism—DPYD—head and neck cancer	8.76e-06	0.000107	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NAT2—head and neck cancer	8.75e-06	0.000107	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MAPK1—head and neck cancer	8.68e-06	0.000106	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EGFR—head and neck cancer	8.68e-06	0.000106	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—AKT1—head and neck cancer	8.65e-06	0.000105	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MAPK1—head and neck cancer	8.61e-06	0.000105	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—PIK3CA—head and neck cancer	8.58e-06	0.000104	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL2—head and neck cancer	8.56e-06	0.000104	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GPX1—head and neck cancer	8.42e-06	0.000103	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—AKT1—head and neck cancer	8.39e-06	0.000102	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—YAP1—head and neck cancer	8.36e-06	0.000102	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCND1—head and neck cancer	8.34e-06	0.000102	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CYP1A1—head and neck cancer	8.33e-06	0.000102	CbGpPWpGaD
Erlotinib—ALB—Metabolism—YAP1—head and neck cancer	8.31e-06	0.000101	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—head and neck cancer	8.3e-06	0.000101	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NAT2—head and neck cancer	8.25e-06	0.0001	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	8.19e-06	9.98e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HRAS—head and neck cancer	8.13e-06	9.9e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—TYMS—head and neck cancer	8.09e-06	9.86e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HRAS—head and neck cancer	8.09e-06	9.85e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	8.06e-06	9.82e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PTEN—head and neck cancer	8.05e-06	9.81e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GSTM1—head and neck cancer	8e-06	9.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—MAPK3—head and neck cancer	7.99e-06	9.73e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—HRAS—head and neck cancer	7.93e-06	9.67e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—AKT1—head and neck cancer	7.85e-06	9.57e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	7.8e-06	9.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NOTCH1—head and neck cancer	7.77e-06	9.46e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—PIK3CA—head and neck cancer	7.72e-06	9.4e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—BCL2—head and neck cancer	7.69e-06	9.37e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—DPYD—head and neck cancer	7.68e-06	9.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CASP8—head and neck cancer	7.66e-06	9.33e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GPX1—head and neck cancer	7.66e-06	9.33e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—MAPK1—head and neck cancer	7.6e-06	9.26e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CYP1A1—head and neck cancer	7.58e-06	9.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDH1—head and neck cancer	7.57e-06	9.22e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PIK3CA—head and neck cancer	7.53e-06	9.17e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	7.42e-06	9.04e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	7.35e-06	8.95e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—head and neck cancer	7.29e-06	8.88e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—YAP1—head and neck cancer	7.28e-06	8.87e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—head and neck cancer	7.27e-06	8.86e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—DPYD—head and neck cancer	7.23e-06	8.81e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—STAT3—head and neck cancer	7.2e-06	8.77e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—AKT1—head and neck cancer	7.18e-06	8.74e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HRAS—head and neck cancer	7.14e-06	8.7e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—AKT1—head and neck cancer	7.14e-06	8.7e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—AKT1—head and neck cancer	7.01e-06	8.53e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NAT2—head and neck cancer	6.99e-06	8.51e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL2—head and neck cancer	6.97e-06	8.5e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRAS—head and neck cancer	6.97e-06	8.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HRAS—head and neck cancer	6.91e-06	8.42e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MAPK3—head and neck cancer	6.88e-06	8.38e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—YAP1—head and neck cancer	6.86e-06	8.36e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	6.85e-06	8.35e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	6.85e-06	8.34e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCND1—head and neck cancer	6.8e-06	8.28e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL2—head and neck cancer	6.77e-06	8.25e-05	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	6.69e-06	8.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—PIK3CA—head and neck cancer	6.6e-06	8.04e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	6.59e-06	8.02e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—BCL2—head and neck cancer	6.57e-06	8.01e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PTEN—head and neck cancer	6.56e-06	7.99e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MAPK1—head and neck cancer	6.54e-06	7.97e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EGFR—head and neck cancer	6.54e-06	7.97e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PTEN—head and neck cancer	6.37e-06	7.76e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2—head and neck cancer	6.36e-06	7.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2—head and neck cancer	6.34e-06	7.72e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PIK3CA—head and neck cancer	6.34e-06	7.72e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—AKT1—head and neck cancer	6.31e-06	7.68e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	6.28e-06	7.65e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	6.25e-06	7.61e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AKT1—head and neck cancer	6.15e-06	7.49e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—DPYD—head and neck cancer	6.13e-06	7.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—head and neck cancer	6.1e-06	7.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—AKT1—head and neck cancer	6.1e-06	7.43e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	5.98e-06	7.28e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—head and neck cancer	5.93e-06	7.22e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STAT3—head and neck cancer	5.87e-06	7.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—head and neck cancer	5.86e-06	7.14e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—YAP1—head and neck cancer	5.82e-06	7.08e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TYMS—head and neck cancer	5.8e-06	7.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2—head and neck cancer	5.79e-06	7.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—head and neck cancer	5.77e-06	7.02e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTM1—head and neck cancer	5.73e-06	6.98e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STAT3—head and neck cancer	5.7e-06	6.94e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PIK3CA—head and neck cancer	5.68e-06	6.92e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK3—head and neck cancer	5.61e-06	6.83e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—head and neck cancer	5.49e-06	6.69e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GPX1—head and neck cancer	5.49e-06	6.68e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	5.48e-06	6.67e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TYMS—head and neck cancer	5.48e-06	6.67e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	5.45e-06	6.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTEN—head and neck cancer	5.45e-06	6.64e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK3—head and neck cancer	5.45e-06	6.63e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOTCH1—head and neck cancer	5.44e-06	6.63e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP1A1—head and neck cancer	5.43e-06	6.62e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTM1—head and neck cancer	5.41e-06	6.59e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—head and neck cancer	5.4e-06	6.58e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NAT2—head and neck cancer	5.39e-06	6.57e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—head and neck cancer	5.39e-06	6.57e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK1—head and neck cancer	5.34e-06	6.5e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—head and neck cancer	5.33e-06	6.5e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—head and neck cancer	5.31e-06	6.47e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—head and neck cancer	5.25e-06	6.4e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GPX1—head and neck cancer	5.18e-06	6.31e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK1—head and neck cancer	5.18e-06	6.31e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—head and neck cancer	5.18e-06	6.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—head and neck cancer	5.18e-06	6.3e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK3—head and neck cancer	5.11e-06	6.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK3—head and neck cancer	5.09e-06	6.2e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTEN—head and neck cancer	5.03e-06	6.13e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TYMS—head and neck cancer	5.02e-06	6.12e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TYMS—head and neck cancer	4.99e-06	6.08e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTM1—head and neck cancer	4.96e-06	6.05e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—head and neck cancer	4.96e-06	6.04e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTM1—head and neck cancer	4.93e-06	6.01e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—head and neck cancer	4.87e-06	5.93e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK1—head and neck cancer	4.86e-06	5.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK1—head and neck cancer	4.85e-06	5.9e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GPX1—head and neck cancer	4.75e-06	5.79e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—DPYD—head and neck cancer	4.73e-06	5.76e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GPX1—head and neck cancer	4.73e-06	5.76e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP1A1—head and neck cancer	4.7e-06	5.73e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP1A1—head and neck cancer	4.68e-06	5.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK3—head and neck cancer	4.65e-06	5.67e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—head and neck cancer	4.64e-06	5.65e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—head and neck cancer	4.63e-06	5.64e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—head and neck cancer	4.63e-06	5.64e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—head and neck cancer	4.51e-06	5.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—head and neck cancer	4.5e-06	5.48e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—head and neck cancer	4.5e-06	5.48e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—YAP1—head and neck cancer	4.49e-06	5.47e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—head and neck cancer	4.48e-06	5.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK1—head and neck cancer	4.43e-06	5.39e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TYMS—head and neck cancer	4.37e-06	5.33e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	4.37e-06	5.32e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—head and neck cancer	4.32e-06	5.27e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—head and neck cancer	4.32e-06	5.26e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK3—head and neck cancer	4.3e-06	5.23e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—head and neck cancer	4.28e-06	5.22e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—head and neck cancer	4.22e-06	5.14e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.22e-06	5.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—head and neck cancer	4.21e-06	5.12e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—head and neck cancer	4.16e-06	5.07e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GPX1—head and neck cancer	4.14e-06	5.04e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TYMS—head and neck cancer	4.12e-06	5.02e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP1A1—head and neck cancer	4.1e-06	4.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK1—head and neck cancer	4.09e-06	4.98e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—head and neck cancer	4.08e-06	4.97e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—head and neck cancer	4.07e-06	4.96e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—head and neck cancer	3.93e-06	4.79e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—head and neck cancer	3.91e-06	4.76e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GPX1—head and neck cancer	3.9e-06	4.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—head and neck cancer	3.89e-06	4.74e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	3.87e-06	4.71e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP1A1—head and neck cancer	3.86e-06	4.71e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	3.84e-06	4.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—head and neck cancer	3.84e-06	4.68e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	3.81e-06	4.64e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—head and neck cancer	3.78e-06	4.61e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—head and neck cancer	3.74e-06	4.56e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—head and neck cancer	3.67e-06	4.47e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—head and neck cancer	3.65e-06	4.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—head and neck cancer	3.56e-06	4.33e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—head and neck cancer	3.55e-06	4.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—head and neck cancer	3.52e-06	4.29e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TYMS—head and neck cancer	3.49e-06	4.25e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—head and neck cancer	3.45e-06	4.2e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—head and neck cancer	3.45e-06	4.2e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—head and neck cancer	3.44e-06	4.19e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GPX1—head and neck cancer	3.31e-06	4.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—head and neck cancer	3.28e-06	4e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP1A1—head and neck cancer	3.27e-06	3.99e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—head and neck cancer	3.27e-06	3.98e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—head and neck cancer	3.23e-06	3.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—head and neck cancer	3.18e-06	3.87e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—head and neck cancer	3.15e-06	3.84e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—head and neck cancer	3.14e-06	3.82e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—head and neck cancer	3.05e-06	3.72e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—head and neck cancer	3.05e-06	3.71e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK3—head and neck cancer	3.01e-06	3.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—head and neck cancer	2.9e-06	3.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK1—head and neck cancer	2.86e-06	3.49e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—head and neck cancer	2.82e-06	3.43e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—head and neck cancer	2.8e-06	3.41e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—head and neck cancer	2.78e-06	3.39e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—head and neck cancer	2.77e-06	3.38e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TYMS—head and neck cancer	2.69e-06	3.28e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.69e-06	3.27e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—head and neck cancer	2.67e-06	3.25e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—head and neck cancer	2.66e-06	3.25e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—head and neck cancer	2.66e-06	3.24e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GPX1—head and neck cancer	2.55e-06	3.11e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1A1—head and neck cancer	2.53e-06	3.08e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—head and neck cancer	2.49e-06	3.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—head and neck cancer	2.48e-06	3.03e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—head and neck cancer	2.44e-06	2.97e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—head and neck cancer	2.44e-06	2.97e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—head and neck cancer	2.43e-06	2.96e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—head and neck cancer	2.4e-06	2.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—head and neck cancer	2.3e-06	2.8e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—head and neck cancer	2.3e-06	2.8e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—head and neck cancer	2.27e-06	2.76e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—head and neck cancer	2.13e-06	2.59e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—head and neck cancer	2.03e-06	2.47e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—head and neck cancer	2e-06	2.44e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—head and neck cancer	1.99e-06	2.42e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—head and neck cancer	1.95e-06	2.37e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—head and neck cancer	1.88e-06	2.29e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—head and neck cancer	1.72e-06	2.1e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—head and neck cancer	1.71e-06	2.08e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—head and neck cancer	1.7e-06	2.07e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—head and neck cancer	1.62e-06	1.98e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—head and neck cancer	1.53e-06	1.87e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—head and neck cancer	1.5e-06	1.83e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—head and neck cancer	1.5e-06	1.83e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—head and neck cancer	1.41e-06	1.72e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—head and neck cancer	1.41e-06	1.71e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—head and neck cancer	1.4e-06	1.7e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—head and neck cancer	1.31e-06	1.6e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—head and neck cancer	1.23e-06	1.49e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—head and neck cancer	1.2e-06	1.46e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—head and neck cancer	1.15e-06	1.41e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—head and neck cancer	9.78e-07	1.19e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—head and neck cancer	9.24e-07	1.13e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—head and neck cancer	7.55e-07	9.19e-06	CbGpPWpGaD
